Equities analysts forecast that Inogen, Inc (NASDAQ:INGN) will announce $64.14 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Inogen’s earnings. The lowest sales estimate is $63.69 million and the highest is $64.59 million. Inogen reported sales of $54.42 million in the same quarter last year, which indicates a positive year over year growth rate of 17.9%. The company is scheduled to report its next quarterly earnings results on Thursday, November 2nd.

On average, analysts expect that Inogen will report full-year sales of $64.14 million for the current financial year, with estimates ranging from $240.71 million to $242.80 million. For the next fiscal year, analysts forecast that the company will post sales of $286.28 million per share, with estimates ranging from $281.31 million to $294.54 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Inogen.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm had revenue of $64.10 million for the quarter, compared to the consensus estimate of $59.99 million. During the same quarter in the previous year, the firm earned $0.25 EPS. The company’s quarterly revenue was up 17.4% compared to the same quarter last year.

A number of analysts recently weighed in on the stock. Needham & Company LLC cut their target price on shares of Inogen from $108.00 to $96.00 and set a “strong-buy” rating on the stock in a research note on Thursday, June 8th. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research lowered shares of Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Piper Jaffray Companies restated a “hold” rating and set a $90.00 target price on shares of Inogen in a research note on Tuesday, September 12th. Finally, J P Morgan Chase & Co upped their target price on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a research note on Monday, June 26th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $91.33.

WARNING: “Zacks: Analysts Expect Inogen, Inc (INGN) Will Post Quarterly Sales of $64.14 Million” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/17/zacks-analysts-expect-inogen-inc-ingn-will-post-quarterly-sales-of-64-14-million.html.

Inogen (NASDAQ:INGN) opened at 100.87 on Friday. The stock has a market cap of $2.09 billion, a P/E ratio of 87.56 and a beta of 1.02. The stock has a 50 day moving average of $95.95 and a 200-day moving average of $87.38. Inogen has a 12 month low of $50.24 and a 12 month high of $105.35.

In other Inogen news, Director Raymond Huggenberger sold 14,000 shares of the stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $92.96, for a total value of $1,301,440.00. Following the transaction, the director now directly owns 7,808 shares in the company, valued at $725,831.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Matt Scribner sold 2,500 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $103.23, for a total transaction of $258,075.00. Following the completion of the transaction, the executive vice president now owns 6,964 shares in the company, valued at $718,893.72. The disclosure for this sale can be found here. Insiders have sold 44,667 shares of company stock worth $4,170,776 over the last 90 days. Insiders own 5.31% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. purchased a new position in Inogen in the first quarter valued at approximately $109,000. Schroder Investment Management Group purchased a new position in Inogen in the second quarter valued at approximately $132,000. Victory Capital Management Inc. increased its stake in Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock valued at $134,000 after purchasing an additional 459 shares during the last quarter. Sei Investments Co. increased its stake in Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after purchasing an additional 443 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in Inogen in the first quarter valued at approximately $203,000.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.